ONCE Stock Price - Spark Therapeutics Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Open $77.01
Day Range 75.39 - 78.43
52 Week Range 41.06 - 91.75
Market Cap $2.88B
Shares Outstanding 37.22M
Public Float 31.72M
Beta 1.67
Rev. per Employee $84.02K
P/E Ratio n/a
EPS $-7.22
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 4.83M 04/30/18
% of Float Shorted 15.22%
Average Volume 650.44K

5 Day	1.66%
1 Month	-4.68%
3 Month	40.68%
YTD	50.45%
1 Year	38.54%

MarketWatch
Other Dow Jones

Spark Therapeutics stock price target raised to $80 from $51 at UBS

May. 16, 2018 at 1:26 p.m. ET
by Tomi Kilgore

Spark Therapeutics loss widens

Spark Therapeutics Inc. ONCE on Tuesday reported a widened 2017 net loss, after booking an R&D impairment charge, as well as higher costs. The Philadelphia-based gene therapy company posted a loss of $253.5 million, or $7.63 a diluted share, compared with a loss of $123.7 million, or $4.29, for the same period the year before.

Feb. 20, 2018 at 7:54 a.m. ET
by MarketWatch.com

Spark Therapeutics downgraded to neutral from overweight at J.P. Morgan

Feb. 14, 2018 at 8:17 a.m. ET
by Tomi Kilgore

Novartis, Spark in vision-loss gene therapy deal

Jan. 25, 2018 at 1:52 a.m. ET

Spark Therapeutics downgraded to underperform from neutral at Wedbush

Jan. 16, 2018 at 8:37 a.m. ET
by Tomi Kilgore

Sarepta is making a bold bet on genetic medicine

Jan. 14, 2018 at 2:18 p.m. ET
by Emma Court

Spark Therapeutics stock price target cut to $66 vs. $75 at Raymond James

Jan. 4, 2018 at 8:18 a.m. ET
by Ciara Linnane

AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC

Jan. 3, 2018 at 1:46 p.m. ET
by Emma Court

AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC

Jan. 3, 2018 at 1:25 p.m. ET
by Emma Court

Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

Dec. 19, 2017 at 11:08 a.m. ET
by Emma Court

Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

Dec. 19, 2017 at 10:52 a.m. ET
by Emma Court

Spark Therapeutics downgraded to neutral from buy at UBS

Dec. 12, 2017 at 1:10 p.m. ET
by Tomi Kilgore

Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting

Dec. 11, 2017 at 3:31 p.m. ET
by Ciara Linnane

Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

Dec. 11, 2017 at 9:40 a.m. ET
by Ciara Linnane

Breaking

Gene-therapy approach to hemophilia finds success in study, Spark stock surges

Dec. 6, 2017 at 5:16 p.m. ET
by Jeremy C. Owens

Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million

Oct. 16, 2017 at 8:35 a.m. ET
by Emma Court

Spark Therapeutics shares jump 7.5% after FDA committee backs blindness treatment

Oct. 13, 2017 at 7:41 a.m. ET
by Ciara Linnane

Spark Therapeutics shares jump 6.5% premarket after FDA committee recommends approval of eye drug

Oct. 13, 2017 at 7:25 a.m. ET
by Ciara Linnane

Bitcoin’s on a tear above $5,000 — and these tech giants could spur it higher

Oct. 12, 2017 at 9:43 a.m. ET
by Barbara Kollmeyer

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Oct. 12, 2017 at 7:41 a.m. ET
by Ciara Linnane

Charting the Market

A graphic look at selected stock activity for the week ended April 13, 2018, Includes Zillow, Alaska Air, and vTv Therapeutics.

Apr. 14, 2018 at 12:01 a.m. ET
on Barron's Online

Why the Deal for AveXis Is a Powerful Vote for Replacement Gene Therapy

Other gene therapy companies stand to gain in the wake of Novartis’s $8.7 billion acquisition

Apr. 9, 2018 at 12:42 p.m. ET
on Barron's Online

Medical Miracles From FDA Inefficiency

Jan. 26, 2018 at 6:05 p.m. ET
on The Wall Street Journal

Corrections & Amplifications

Jan. 4, 2018 at 9:29 p.m. ET
on The Wall Street Journal

CVS, Walgreens Say Drug Prices Are Easing After Years of Ballooning

Jan. 4, 2018 at 2:23 p.m. ET
on The Wall Street Journal

Drug Firm Spark Therapeutics Will Charge $850,000 for Vision-Loss Gene Therapy

Jan. 3, 2018 at 8:30 a.m. ET
on The Wall Street Journal

Small Is Best for Biotech ETFs

Dec. 22, 2017 at 11:17 p.m. ET
on Barron's

FDA Blesses Blindness Treatment That Could Cost $1 Million

Dec. 19, 2017 at 1:03 p.m. ET
on The Wall Street Journal

There’s Still Life in Spark

Dec. 15, 2017 at 10:48 p.m. ET
on Barron's

Stocks to Watch: Bank of America, Wells Fargo, Amazon, HP, Netflix, Tesla, McDonald’s

Oct. 13, 2017 at 9:15 a.m. ET
on The Wall Street Journal

Gene Therapy Is Nearing a Major Breakthrough

Sep. 25, 2017 at 3:15 p.m. ET
on Barron's

Trump Travel Ban Is a Wake-Up Call for Business

Feb. 1, 2017 at 1:50 p.m. ET
on The Wall Street Journal

9 Oversold Drug Stocks With Big-Gain Potential

Feb. 17, 2016 at 11:24 a.m. ET
on Barron's

Two Biotechs at Compelling Entry Points

Oct. 7, 2015 at 10:16 a.m. ET
on Barron's

Gene Therapy for Visually Impaired Shows Promise

Oct. 5, 2015 at 6:08 p.m. ET
on The Wall Street Journal

Etsy Poised to Be One of 2015′s Hottest IPOs

Apr. 16, 2015 at 2:23 p.m. ET
on The Wall Street Journal

Other News
Press Releases

bluebird bio: Gene Therapy Best In Class

May. 16, 2018 at 11:31 a.m. ET
on Seeking Alpha

Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?

May. 15, 2018 at 2:48 p.m. ET
on Seeking Alpha

Genomic Medicine: Catch The Gene Therapy Wave

May. 14, 2018 at 3:12 p.m. ET
on Seeking Alpha

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

May. 14, 2018 at 11:37 a.m. ET
on Seeking Alpha

Recent Developments, Recommendations for JAZZ in May

In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.

May. 10, 2018 at 10:24 a.m. ET
on MarketRealist.com

Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates

Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.

May. 9, 2018 at 10:32 a.m. ET
on Zacks.com

Stifel Nicolaus Keeps Their Buy Rating on Spark Therapeutics

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on ...[...]

May. 9, 2018 at 8:45 a.m. ET
on SmarterAnalyst

Cowen & Co. Maintains Their Buy Rating on Spark Therapeutics

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) ...[...]

May. 8, 2018 at 6:08 p.m. ET
on SmarterAnalyst

Mizuho Securities Maintains a Buy Rating on Spark Therapeutics

Mizuho Securities analyst Difei Yang maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today ...[...]

May. 8, 2018 at 4:14 p.m. ET
on SmarterAnalyst

10-Q: SPARK THERAPEUTICS, INC.

May. 8, 2018 at 4:25 p.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Spark Therapeutics 2018 Q1 - Results - Earnings Call Slides

May. 8, 2018 at 2:42 p.m. ET
on Seeking Alpha

Spark Therapeutics Gets a Buy Rating from William Blair

William Blair analyst Raju Prasad maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. ...[...]

May. 8, 2018 at 1:47 p.m. ET
on SmarterAnalyst

Spark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q1 2018 Results - Earnings Call Transcript

May. 8, 2018 at 1:29 p.m. ET
on Seeking Alpha

Spark Therapeutics Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today ...[...]

May. 8, 2018 at 10:15 a.m. ET
on SmarterAnalyst

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions And Taking Advantage Of Weakness In The I-O Space

May. 7, 2018 at 3:40 p.m. ET
on Seeking Alpha

Premarket analyst action - healthcare

May. 1, 2018 at 8:22 a.m. ET
on Seeking Alpha

Mizuho Securities Reiterates Their Buy Rating on Spark Therapeutics

In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on ...[...]

May. 1, 2018 at 4:33 a.m. ET
on SmarterAnalyst

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

May. 1, 2018 at 2:41 a.m. ET
on Seeking Alpha

Cantor Fitzgerald Sticks to Its Buy Rating for Spark Therapeutics

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today ...[...]

Apr. 30, 2018 at 10:08 a.m. ET
on SmarterAnalyst

Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation

Apr. 30, 2018 at 2:19 a.m. ET
on Seeking Alpha

Global E-Commerce Logistics Market Competitive landscape: FedEx, Kenco Group Inc, Ceva Holdings Inc

May. 9, 2018 at 1:29 a.m. ET
on marketresearch.biz

Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

May. 8, 2018 at 7:30 a.m. ET
on GlobeNewswire

Global Gene Therapy Market Competitive landscape: Amgen Inc, Novartis, Transgene SA, Kite Pharma Inc

May. 8, 2018 at 1:05 a.m. ET
on marketresearch.biz

Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital -- What Drives Growth in Today's Competitive Landscape

Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital -- What Drives Growth in Today's Competitive Landscape

May. 1, 2018 at 7:30 a.m. ET
on GlobeNewswire

Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights

May. 1, 2018 at 7:30 a.m. ET
on GlobeNewswire

Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights

May. 1, 2018 at 7:30 a.m. ET
on Globe Newswire

Spark Therapeutics Sells Priority Review Voucher for $110 Million

Apr. 30, 2018 at 8:07 a.m. ET
on GlobeNewswire

Veeva Commercial & Medical Summit Brings Together World’s Most Innovative Life Sciences Companies

Apr. 23, 2018 at 7:03 a.m. ET
on BusinessWire - BZX

Pre-Market Technical Scan on Biotech Equities -- Sorrento Therapeutics, Spark Therapeutics, Synthetic Biologics, and TG Therapeutics

Mar. 15, 2018 at 6:30 a.m. ET
on PR Newswire - PRF

Global Gene Therapy Market Analysis & Forecast to 2022

Mar. 13, 2018 at 9:08 a.m. ET
on PR Newswire - PRF

Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide -- New Horizons, Emerging Trends, and Upcoming Developments

Report: Exploring Fundamental Drivers Behind Accelerate Diagnostics, FTI Consulting, Spark Therapeutics, Achaogen, Oxford Industries, and Kronos Worldwide -- New Horizons, Emerging Trends, and Upcoming Developments

Mar. 2, 2018 at 8:15 a.m. ET
on GlobeNewswire

United States : CEOs Leading Scientific Breakthroughs at Otsuka and Spark Therapeutics to Keynote Veeva Commercial & Medical Summit

Mar. 1, 2018 at 6:35 p.m. ET
on Euclid Tenders Info

Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases

Mar. 1, 2018 at 7:21 a.m. ET
on ACCESSWIRE

CEOs Leading Scientific Breakthroughs at Otsuka and Spark Therapeuticsto Keynote Veeva Commercial & Medical Summit

Feb. 28, 2018 at 7:03 a.m. ET
on BusinessWire - BZX

Today's Research Reports on Trending Tickers: Acadia Healthcare and Spark Therapeutics

Feb. 23, 2018 at 8:20 a.m. ET
on ACCESSWIRE

Spark Therapeutics to Participate in Multiple Conferences in March

Feb. 23, 2018 at 7:30 a.m. ET
on GlobeNewswire

Spark Therapeutics to Participate in Multiple Conferences in March

Feb. 23, 2018 at 7:30 a.m. ET
on Globe Newswire

Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress

Feb. 20, 2018 at 7:30 a.m. ET
on GlobeNewswire

Spark Therapeutics, Inc. to Host Earnings Call

Feb. 20, 2018 at 6:12 a.m. ET
on ACCESSWIRE

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

Feb. 13, 2018 at 7:31 a.m. ET
on GlobeNewswire

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 21 Full Ratings

Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space

Apr. 9, 2018 at 9:11 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For February 14, 2018

Feb. 14, 2018 at 9:33 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For February 13, 2018

Feb. 13, 2018 at 9:22 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Immunomedics Inc.	3.59%	$3.14B
Illumina Inc.	1.78%	$38.77B
Harvard Bioscience Inc.	-3.13%	$172.7M
FibroGen Inc.	2.64%	$4.27B

Competitor Data Provided By

Dow	24,756.56	50.15	0.20%
S&P 500	2,722.10	10.65	0.39%
Nasdaq	7,399.23	47.61	0.65%
GlobalDow	3,092.99	3.79	0.12%
Gold	1,291.20	0.90	0.07%
Oil	71.45	0.14	0.20%

Spark Therapeutics Inc.

$ 77.36

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Spark Therapeutics stock price target raised to $80 from $51 at UBS

Spark Therapeutics downgraded to neutral from overweight at J.P. Morgan

Spark Therapeutics downgraded to underperform from neutral at Wedbush

Spark Therapeutics stock price target cut to $66 vs. $75 at Raymond James

AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC

Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

Spark Therapeutics downgraded to neutral from buy at UBS

Spark Therapeutics shares jump 6.5% premarket after FDA committee recommends approval of eye drug

Stocks

Columns

Authors

Topics

^$ 77.36